Physician profile
Donald Thomas
NPI 1730167545
$470,632.36
in general payments reported to CMS, 2019-2025
30 companies · $110K in 2025
The $110K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,683 · 2020: $21K · 2021: $69K · 2022: $62K · 2023: $144K · 2024: $59K · 2025: $110K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $204K · Consulting Fee: $50K · Travel and Lodging: $48K · Food and Beverage: $11K · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $203,907.00 |
| Consulting Fee | $50,029.00 |
| Travel and Lodging | $48,286.75 |
| Food and Beverage | $10,536.54 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $300,906.15 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $144,894.55 | 2020-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $11,527.96 | 2021-2025 | Lupkynis |
| Genentech USA, INC. | $7,167.07 | 2019-2025 | Actemra, Ocrevus Zunovo |
| Janssen Biotech, INC. | $1,232.77 | 2019-2025 | Tremfya |
| Mallinckrodt Hospital Products INC. | $1,207.18 | 2022-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $1,101.21 | 2019-2025 | |
| Amgen INC. | $747.91 | 2019-2025 | Krystexxa, Tavneos, Uplizna |
| Abbvie INC. | $383.21 | 2019-2025 | Humira, Rinvoq, Qulipta |
| Ani Pharmaceuticals, INC. | $233.31 | 2023-2025 | Purified Cortrophin Gel |
| Pfizer INC. | $188.62 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $169.55 | 2019-2025 | Orencia |
| Ucb, INC. | $152.05 | 2023-2025 | Bimzelx, Cimzia |
| Fresenius Kabi USA, LLC | $125.12 | 2023-2025 | Idacio |
| Horizon Therapeutics Plc | $82.41 | 2019-2023 | Krystexxa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $79.53 | 2023-2025 | Zilretta, Iovera |
| Alexion Pharmaceuticals, INC. | $55.83 | 2024 | Strensiq, Ultomiris |
| Hikma Pharmaceuticals USA | $47.17 | 2019-2020 | |
| Radius Health, INC. | $44.80 | 2024-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $41.88 | 2019 | |
| Genzyme Corporation | $39.98 | 2023-2025 | |
| Sandoz INC. | $33.20 | 2024 | Hyrimoz |
| Sobi, INC | $32.88 | 2025 | |
| Invivyd INC | $25.32 | 2025 | Pemgarda |
| Saluda Medical Americas, INC. | $23.75 | 2025 | Evoke |
| Novo Nordisk INC | $22.23 | 2025 | Wegovy |
| Tersera Therapeutics LLC | $18.67 | 2024 | Quzyttir |
| Sanofi Pasteur INC. | $17.87 | 2019 | |
| Pacira Therapeutics, INC. | $17.41 | 2019 | |
| Fidia Pharma USA INC. | $12.77 | 2023 | Hymovis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.